| __timestamp | Mesoblast Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 205018000 |
| Thursday, January 1, 2015 | 23783000 | 392709000 |
| Friday, January 1, 2016 | 29763000 | 299694000 |
| Sunday, January 1, 2017 | 12065000 | 397061000 |
| Monday, January 1, 2018 | 5508000 | 434100000 |
| Tuesday, January 1, 2019 | 75173000 | 782200000 |
| Wednesday, January 1, 2020 | 81497000 | 1119900000 |
| Friday, January 1, 2021 | 85731000 | 2437500000 |
| Saturday, January 1, 2022 | 63572000 | 1560400000 |
| Sunday, January 1, 2023 | 54922000 | 1815800000 |
| Monday, January 1, 2024 | 41070000 | 1970500000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, cost efficiency is a critical metric. This analysis delves into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Mesoblast Limited from 2014 to 2023. Regeneron, a leader in the industry, has seen its cost of revenue grow significantly, peaking at approximately $2.44 billion in 2021, a staggering 1,100% increase from 2014. In contrast, Mesoblast's cost of revenue, while much smaller, has shown a more modest increase, peaking at around $85.7 million in 2021, a 237% rise from 2014. This stark contrast highlights Regeneron's expansive growth and operational scale compared to Mesoblast's more conservative trajectory. Notably, data for Regeneron in 2024 is missing, indicating potential shifts or reporting changes. This comparison underscores the diverse strategies and market positions of these two companies in the ever-evolving pharmaceutical sector.
Cost of Revenue: Key Insights for AbbVie Inc. and Mesoblast Limited
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Mesoblast Limited's Expenses
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Incyte Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Mesoblast Limited
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Mesoblast Limited